Palisade Bio, Inc. (PALI)

Palisade Bio Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.25	-	-	-
Gross Profit	-	0.25	-	-	-
Selling, General & Admin	5.8	6.2	8.76	9.31	6.2
Research & Development	9.06	6.89	6.55	2.43	3.1
Operating Expenses	14.86	13.1	15.31	11.74	9.3
Operating Income	-14.86	-12.85	-15.31	-11.74	-9.3
Interest Expense	-0.01	-0.02	-0.01	-3.08	-1.08
Interest & Investment Income	0.5	0.7	0.2	-	-
Other Non Operating Income (Expenses)	-0.07	0.09	1.27	18.04	0.05
EBT Excluding Unusual Items	-14.44	-12.08	-13.85	3.22	-10.32
Merger & Restructuring Charges	-	-0.23	-0.41	-	-
Other Unusual Items	-	-	-	0.28	-
Pretax Income	-14.44	-12.3	-14.26	-26.62	-10.32
Net Income	-14.44	-12.3	-14.26	-26.62	-10.32
Preferred Dividends & Other Adjustments	-	0.02	0.29	-	-
Net Income to Common	-14.44	-12.32	-14.55	-26.62	-10.32
Shares Outstanding (Basic)	1	0	0	0	-
Shares Outstanding (Diluted)	1	0	0	0	-
Shares Change (YoY)	210.62%	677.03%	370.85%	-	-
EPS (Basic)	-10.19	-27.01	-247.89	-2144.20	-
EPS (Diluted)	-10.19	-27.01	-247.95	-2546.13	-
Free Cash Flow	-12.19	-11.14	-13.37	-14.77	-4.77
Free Cash Flow Per Share	-8.61	-24.42	-227.82	-1185.25	-
Gross Margin	-	100.00%	-	-	-
Operating Margin	-	-5138.00%	-	-	-
Profit Margin	-	-4926.40%	-	-	-
Free Cash Flow Margin	-	-4454.80%	-	-	-
EBITDA	-14.86	-12.84	-15.31	-11.74	-9.29
D&A For EBITDA	0	0	0	0	0
EBIT	-14.86	-12.85	-15.31	-11.74	-9.3

Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q